Opinion|Videos|March 11, 2024
MIRASOL trial and DESTINY-PanTumor02 Trial Overview
Ronald D. Alvarez, MD, MBA, gives an analysis of the MIRASOL and DESTINY-PanTumor02 trials, including a comparison of study arms and discussion of HER2/neu targeting.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata
2
First Clinical Evidence of Gene Editing, Epigenetic Silencing of HBV cccDNA
3
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
4
5 Notable Oncology FDA Approvals Granted in May
5